<DOC>
	<DOCNO>NCT00357448</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , denileukin difitox , may stimulate immune system different way may prevent tumor cell grow . PURPOSE : This phase I trial study side effect best dose denileukin diftitox treat patient advanced refractory ovarian cancer , primary peritoneal carcinoma , epithelial fallopian tube cancer .</brief_summary>
	<brief_title>Denileukin Diftitox Used Treating Patients With Advanced Refractory Ovarian Cancer , Primary Peritoneal Carcinoma , Epithelial Fallopian Tube Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate maximum tolerate dose intraperitoneal administration ONTAK . SECONDARY OBJECTIVES : I . To evaluate change number Tregs peritoneum administration ONTAK . II . To evaluate change number Tregs peripheral blood administration ONTAK . III . To assess clinical impact ONTAK tumor burden serial measurement CA-125 . IV . To assess level circulate cytokine IL-2 , IL-6 , IL-10 , TGF-beta2 , TNF-alpha peritoneum peripheral blood I.P . ONTAK . OUTLINE : This dose escalation study . Patients receive intraperitoneal denileukin diftitox least 15 minute day 1-3 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos denileukin diftitox maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow 1 2 week , monthly 3 month , 6 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Endometrioid</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Cystadenocarcinoma , Mucinous</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patients histologic diagnosis epithelial ovarian carcinoma , primary peritoneal carcinoma , epithelial fallopian tube carcinoma Patients follow histologic epithelial cell type eligible : Serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , transitional cell carcinoma , mixed epithelial carcinoma Patients advance stage refractory ovarian carcinoma : patient unable achieve first complete remission ( CR ) first second line chemotherapy OR patient disease relapse achieve second CR Patients must 30 day last chemotherapy ; previous chemotherapy must include platinumbased regimen paclitaxel ( Taxol ) Patients must undergo primary debulking surgery Patients must peritoneal catheter suitable I.P . infusion White blood cell count ( WBC ) &gt; 3.0 THOU/ul Serum creatinine = &lt; 2.5 mg/dL ALT = &lt; 2.5 x upper limit normal AST = &lt; 2.5 x upper limit normal Total bilirubin = &lt; 2.0 x upper limit normal Albumin &gt; = 3.0 g/dL Subjects must Performance Status Score ( Zubrod/SWOG Scale ) = &lt; 2 Subjects must recover major infection and/or surgical procedure , opinion investigator , significant active concurrent medical illness preclude protocol treatment Lymphocytes &gt; 1.0 THOU/ul Platelets &gt; = 100 THOU/ul Prior treatment ONTAK ( DAB389IL2 ) DAB486IL2 Known history hypersensitivity diphtheria toxin IL2 Moderate ( symptomatic requiring use diuretic ) severe ( symptomatic require paracentesis invasive intervention ) ascites Active autoimmune disease Known history pulmonary disease except controlled asthma Known history significant cardiac disease Concurrent malignancy require active treatment Clinical radiological evidence acute bowel obstruction within 30 day enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>